Education
About Us
Working with TipRanks
Follow Us
Arcoma AB (SE:ARCOMA)
:ARCOMA
Top Page
Arcoma AB
(ARCOMA)
Select Model
Select Model
Rating:58Neutral
Price Target:
kr7.50
▲(4.17% Upside)
The score is supported by a very strong, low-leverage balance sheet, but is held back by deteriorating TTM operating performance (revenue and margin compression) and weaker free cash flow. Technical signals add additional pressure given a clear downtrend versus key moving averages and negative MACD, while valuation is only moderate with no dividend data provided.
Arcoma AB (ARCOMA) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr103.88M
Dividend YieldN/A
Average Volume (3M)22.73K
Price to Earnings (P/E)22.6
Beta (1Y)0.27
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees31
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)0.10
Shares Outstanding14,308,510
10 Day Avg. Volume31,356
30 Day Avg. Volume22,732
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)2.39
Price to Sales (P/S)0.90
P/FCF Ratio11.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)kr140.00M
Arcoma AB Business Overview & Revenue Model
Company DescriptionArcoma AB develops, produces, and provides radiology solutions worldwide. It offers digital x-ray and radiography systems for radiographic applications, as well as for use in general, eneral, muscle/skeleton, thoratic, pediatric, and trauma/resus clinics. The company sells its products through OEM partners. Arcoma AB was founded in 1990 and is based in Växjö, Sweden.
How the Company Makes Money
Arcoma AB Financial Statement Overview
Summary
Financials are mixed. The balance sheet is a clear strength (effectively zero debt, growing equity), supporting resilience. However, TTM revenue is down sharply and margins have compressed versus 2024, with weaker free cash flow and historically uneven cash generation despite remaining positive in TTM.Income Statement
TTM (Trailing-Twelve-Months) revenue is down sharply and profitability has softened versus 2024 (gross margin ~33% vs ~40%, net margin ~3% vs ~7%). That said, the company remains profitable in TTM with positive operating profit, and results are materially improved from the 2021 loss-making year. Overall, earnings quality looks decent but the near-term revenue and margin compression is a clear headwind.63
Positive
Balance Sheet
Balance sheet is a major strength: total debt is effectively zero in TTM and 2024, and equity has grown meaningfully, supporting a larger asset base. Returns on equity are positive in TTM (mid-single digits) and were strong in 2024, though they have cooled alongside the profit slowdown. Key watch-out is less about leverage (very low) and more about maintaining profitability so returns don’t drift further down.86
Very Positive
Cash Flow
Cash generation is positive in TTM, but has weakened notably: free cash flow fell materially versus 2024 and conversion of operating cash flow into earnings is lower in TTM than prior years. The business has also shown volatility historically, including negative cash flow in 2021–2022 and uneven free cash flow since. Strength is that both operating cash flow and free cash flow are positive in TTM; weakness is the sharp step-down and inconsistency.54
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 132.94M | 156.81M | 163.01M | 125.05M | 117.13M | 117.42M |
| Gross Profit | 43.32M | 62.61M | 57.91M | 50.45M | 41.65M | 45.25M |
| EBITDA | 15.54M | 21.96M | 6.11M | 4.68M | -6.66M | 4.97M |
| Net Income | 4.35M | 11.18M | 2.56M | 1.90M | -7.47M | 1.36M |
Balance Sheet | ||||||
| Total Assets | 97.97M | 80.46M | 81.96M | 100.33M | 79.27M | 95.03M |
| Cash, Cash Equivalents and Short-Term Investments | 23.88M | 13.38M | 5.00M | 9.66M | 4.83M | 8.58M |
| Total Debt | 0.00 | 0.00 | 3.87M | 25.09M | 16.61M | 17.01M |
| Total Liabilities | 24.58M | 21.13M | 33.30M | 54.46M | 35.23M | 45.50M |
| Stockholders Equity | 73.39M | 59.33M | 48.66M | 45.88M | 44.04M | 49.53M |
Cash Flow | ||||||
| Free Cash Flow | 4.07M | 12.06M | 16.61M | -4.35M | -6.12M | -4.86M |
| Operating Cash Flow | 9.78M | 18.84M | 19.16M | -179.00K | -1.93M | 6.85M |
| Investing Cash Flow | -6.60M | -6.78M | -2.55M | -4.17M | -4.19M | -11.70M |
| Financing Cash Flow | 10.42M | -3.87M | -21.22M | 9.65M | 2.40M | 11.23M |
Arcoma AB Peers Comparison
UnderperformOutperform
Sector (51)
SE:ARCOMA
Arcoma AB
7.26
-3.59
-33.09%
DE:LS60
Clinical Laserthermia Systems AB Class B
0.69
0.38
125.16%
DE:2OK
SpectraCure AB
0.01
-0.06
-85.71%
DE:LUR
Luxbright AB
0.04
-0.03
-40.63%
DE:5YL
BrainCool AB
0.05
-0.05
-47.52%
SE:NEOLA
Neola Medical AB
0.85
-1.61
-65.53%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.